Predictive Health Intelligence

The  Patient Perspective 🤒  At Predictive Health Intelligence, our mission is to help end the late diagnosis of liver disease. That’s why we created hepatoSIGHT – a case-finding search engine designed to help clinicians make better use of historical medical data to proactively identify people with liver disease earlier. John, a retired NHS worker in his late 60s, is one of the many individuals who have benefitted from hepatoSIGHT, and he wanted to share his story. Like many people, John had undergone regular blood tests over the years with no worrying results. Having recently made some positive lifestyle changes, such as giving up drinking, he felt confident about his health. However, when doctors using hepatoSIGHT saw something unusual in his past tests, John received a letter from Somerset NHS Foundation Trust inviting him to clinic so they could take a closer look at his liver health. After further blood tests and a consultation with doctors at Somerset NHS Foundation Trust, it was suspected that John might have metabolic-related liver disease, a common and often benign condition but one that can progress to advanced liver diseases like cirrhosis and liver cancer if left unchecked. An ultrasound-based non-invasive test called a FibroScan confirmed the diagnosis, but due to the analysis provided by hepatoSIGHT, it had been caught relatively early. John received advice on how to prevent his condition worsening, and will benefit from annual monitoring just in case things do progress. To others who might receive a similar letter, John’s message is simple: “Don’t panic! It’s always good to investigate what’s going on. When there are expert people prepared to try and help, you should take them up on it.” This is just one of many stories where hepatoSIGHT has helped clinicians uncover liver disease early, allowing for timely, preventative, and cost-effective care.  Stay tuned over the coming weeks to learn more about our impact, one patient at a time. #LiverHealth #PatientEngagement #PublicHealth

🌍 Mind the gap — a public health approach to the care gaps in liver disease detection and prevention. 👉 What are the current care gaps? 🎓 Awareness and education: While the liver health community works hard to raise awareness, more support is needed from healthcare systems and governments to drive real change. Unfortunately, liver disease still carries a stigma, often seen as 'self-inflicted,' when in reality, genetics and environmental factors play significant roles—similar to conditions like diabetes and heart disease. Also, liver disease often progresses without symptoms, making early detection difficult. Improving the public's understanding of risk factors is crucial to enabling early intervention and preventing disease progression. ⌛ Late diagnosis: Many people are diagnosed with liver disease at advanced stages due to its silent progression. This late diagnosis limits curative treatment options and increases the risk of progression to liver cancer. Ideally, diagnosis should occur in a primary care setting, but this often doesn't happen. In fact, three-quarters of people with cirrhosis are only diagnosed when they experience life-threatening symptoms at a crisis point[1]. One study of UK BioBank participants found that 83% of those who developed chronic liver disease were diagnosed late[2]. 🏥 Access to care: Liver disease disproportionately affects people from the most deprived areas. In the UK, people in the most deprived regions face nearly four times the risk of dying from liver disease compared to those in the least deprived. Rates of hospitalization and death are also higher in the North of England than in the South[3]. 👉 Why is this a public health issue? Liver disease places a significant burden on society, with most deaths occurring during working age. It's the second leading cause of lost working years in England[4]. Chronic liver disease that progresses to cirrhosis is a major risk factor for primary liver cancer, yet many chronic liver conditions are preventable. 👉 What can we do? Raise awareness and understanding of liver disease risk factors. Prioritise policies that focus on prevention and early disease identification. Address health inequalities that drive poor liver health outcomes. Learn more about how we're working to address care gaps in liver disease: https://lnkd.in/eKs4-Mjn Sources: https://lnkd.in/efWbQ9kc https://lnkd.in/etgJGPm8 https://lnkd.in/eUdJxz-h https://lnkd.in/eCx7Sug4 #PublicHealth #LiverDiseaseAwareness #HealthcareEquity

🔬 The challenges of conducting multi-centre liver disease trials 🔬 As research into liver disease grows, clinical trials in this area face increasing challenges. While it’s encouraging to see a greater understanding of the societal impact of liver disease, this progress brings unique hurdles for researchers. 🔎 Site selection: Finding trial sites with the necessary experience in liver disease is difficult. Experienced centres are often stretched thin, and using less experienced sites can introduce inefficiencies and inconsistencies, complicating the trial process. 🌍 Managing enrolment criteria: Liver disease trials often have incredibly strict inclusion and exclusion criteria. Ensuring these are applied consistently across all sites is critical, especially in international studies where differences in standardisation across countries and sites can create additional challenges in recruitment and data collection. 🧑🏼🤝🧑🏿 Recruitment: The pool of eligible participants is limited, and growing competition between trials makes recruitment before enrolment deadlines even more difficult. Diseases like MASH often progress asymptomatically and lack ubiquitous diagnostic approaches, further complicating recruitment efforts and leading to high screen failure rates. The good news? Emerging technologies designed to support clinical operations in liver disease trials are helping to address these challenges. Learn how we can help: https://lnkd.in/eKs4-Mjn #ClinicalTrials #LiverDisease #MASH  

🔬 New Research on Improving Liver Disease Pathways 🔬    To end the late diagnosis of liver disease, we created hepatoSIGHT. To ensure it works and quantify its utility, we've been conducting a whole host of research projects in various areas of medicine. In partnership with our clinical partners, we're proud to be presenting 3 of our latest abstracts at this year's The Liver Meeting in San Diego.    👉 Data Driven Clinical Trial Recruitment - From the Common to the Rare. 💡 Why is this important? This abstract demonstrates and quantifies the power of hepatoSIGHT for improving clinical trials. We hope this will lead to better, more effective treatments for liver disease, being available for use sooner. 👉 The Patient Experience of a New ‘Referral’ Pathway for Liver Disease in the Somerset Liver Improvement Project. 💡 Why is this important? This abstract presents the first real-world data on patients' experiences of hepatoSIGHT and the Somerset Liver Improvement Project. We'll use this information to guide how we and our partners interact with patients. 👉 Defining the Data Requirement to Improve Hepatitis D Co-Infection Detection in the United Kingdom: The Somerset Liver Improvement Project. 💡 Why is this important? This abstract shows how hepatoSIGHT may be used to identify undiagnosed hepatitis D patients in the UK. We hope that our data-driven case-finding approach can play a key role in eliminating hepatitis D - in line with the World Health Organization's mandate. Want to learn more?  👉 Visit our posters during The Liver Meeting.  👉 Meet the team at Booth 1411  👉 Visit our website https://lnkd.in/eSMDDMPu    #TLM2024 #AASLD #LiverResearch 

Meet the Founder: Our Managing Director Neil Stevens CHCIO 🎓 What's your background? I have a background in information management, a degree in psychology, and a post-graduate qualification in artificial intelligence. Over the course of 25 years, I worked in the NHS, managing clinical information systems that support operational activities across Trusts. I have been running a successful management consulting company for the past 15 years, providing services to NHS Trusts and information system suppliers to NHS and Social Care clients. Throughout my 40-year career, I've been deeply passionate about how technology can drive improvements in health and social care. I've led numerous IT-enabled change management programmes at national and local levels, all aimed at enhancing the delivery of healthcare services.   💡 How did the idea come about? My co-founder, Tim Jobson, and I worked together in the NHS on several digital transformation projects. We kept in touch, and back in 2018, we had one of those chance meetings. We sat down with a soda and lime to discuss his frustrations about the number of people who attend his liver clinic, but when their condition is too far advanced to provide any effective treatments. A common thread was that when he looked at their medical records, there were often blood tests carried out over the years and when he looked at them, he could see an indication of some disease progression and deterioration. Whilst this is visible if an individual's record is being looked at, there were no systems that allowed clinicians to ask: "show me all of the people for whom these particular patterns are present". With my background in healthcare information systems and his clinical insight, we decided to work together to solve this problem. We received a grant from the NIHR (National Institute for Health and Care Research) to support the development of our case-finding methodology and the system to support it - hepatoSIGHT™. The system is now developed, and over 700 people who could benefit from an appointment in the liver clinic or further diagnostic tests have already been identified.   🔍 What drives your work? A core motivation for me is advancing interoperability between IT systems within the healthcare sector and harnessing the huge value of data, which, in many cases, already exists. I believe that better use of information is critical to redesigning healthcare delivery in more efficient and effective ways. Technology has incredible potential to improve patient outcomes, I'm always excited about discovering new ways to harness that potential.   🌍 What's next? Thanks to recent regulatory milestones, we're on the verge of helping a much broader population, which is incredibly exciting. The next phase will focus on expanding our reach, from a technology standpoint, we aim to broaden the range of users we support. There is also significant potential to move our approach into other disease areas. #Leadership #FounderStories

Meet us in San Diego! We are delighted to be exhibiting again this year at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting. As one of the world's largest hepatology conferences, it gives us an invaluable opportunity to showcase our latest research and demonstrate how we enable clinicians to identify people with liver disease at an earlier stage. It also allows us to engage with other experts in liver health and drive the conversation around ending the late diagnosis of liver disease. 📍Meet us at booth 1411 🗓️ November 15 - 19 We’ll be presenting some exciting research with our clinical collaborators, so watch this space! #AASLD #TLM24 #LiverDisease | Tim Jobson | Neil Stevens CHCIO | Mark Wall | James H.

Our Medical Director, Tim Jobson, has been at BASL (THE BRITISH ASSOCIATION FOR THE STUDY OF THE LIVER) annual meeting, engaging with fellow experts in liver disease and exploring the role of hepatoSIGHT in enhancing liver disease pathways. We are also incredibly proud to have our clinical partners at Somerset NHS Foundation Trust presenting five studies that feature the hepatoSIGHT technology! These studies demonstrate the impact the technology can have on preventative medicine, early diagnosis, improving patient pathways, and enhancing the patient experience. If you're attending, be sure to reach out. ALMuthana Mohamed | Christina Owen #LiverDisease #ClinicalTrials #BASL2024

Clinicians and health systems share the same goal: to provide the most effective care to those who need it most. Our Medical Director, Tim Jobson, spent decades in the NHS, treating patients with advanced liver disease where treatment options were often limited. This experience drove him and Neil Stevens to find a better approach. Empowered with data and actionable insights, clinicians can proactively identify people in need of care, offering the potential for earlier, more curative, and more cost-effective treatments. Learn about how we're ending the late diagnosis of liver disease 👇 https://lnkd.in/eNVvS_ZT #liverdisease #publichealth #NHSEngland

October is for livers. The Global Liver Institute (GLI) launched the #OctoberIs4Livers campaign in 2018 to raise awareness about liver cancer, improve clinical practices, and influence prevention, detection, and treatment policies. 2024's theme is "Addressing Disparities in Liver Cancer Care." Let's look at the disparities in liver cancer. ⭕️ People living in economically disadvantaged areas of Europe face a higher incidence of liver cancer[1]. ⭕️ In the UK, nearly 40% of liver cancer diagnoses occur through emergency presentations, while only 11.7% are diagnosed via the two-week wait referral pathway. Patients from lower socioeconomic backgrounds are more likely to be diagnosed in emergency situations[2]. ⭕️ Late diagnosis of liver cancer reduces the survival rates. In England, those diagnosed at the earliest stage have a 45% 4-year survival rate, however at the latest stage this drops to 5%[3]. Liver cancer is a public health problem. ⭕️ Liver cancer risk varies significantly across ethnicities, socioeconomic groups, and geographic regions in England. This complexity calls for tailored public health strategies that address early detection in different populations[2]. ⭕️ In England, the NHS England #Core20Plus5 programme provides a mandate for tackling inequalities. Tackling the late diagnosis of chronic liver disease, which can lead to liver cancer, within areas of deprivation needs to be a fundamental part of this approach. We are helping to overcome this. 🟢 In research with our collaborations, data showed that our novel case-finding tool has the potential to identify patients from areas of deprivation at risk of advanced liver disease.[4] 🟢 In practice, our customers are using hepatoSIGHT to help identify people with undiagnosed liver disease and liver cancer to deliver preventative care and early diagnosis. --- Learn more about the GLI's work in addressing health inequalities in liver cancer by joining their weekly roundtable: 📍 Thursdays at 1pm EST https://lnkd.in/ebKDFueq --- #OctoberIs4Livers #LiverCancer #HealthEquity 1. https://lnkd.in/eE6hNz5y 2. https://lnkd.in/evTqG5gh 3. https://lnkd.in/eFNUK__S 4. https://lnkd.in/ecMkHJuc

🔍 Keeping people out of A&E: Why early diagnosis matters for liver health.   Early diagnosis, care in the right setting, and preventative healthcare are not just buzzwords—they are critical to improving public health and easing the pressure on the NHS.   When it comes to liver health, identifying disease early opens up more treatment options, with higher chances of success. In many cases, simple lifestyle changes can reverse the damage, and various treatments are available for chronic conditions. The liver's remarkable ability to regenerate also makes it a prime focus for early diagnosis.   But what happens when patients end up in A&E with liver disease? By then, the disease is often in its later stages, limiting treatment options and reducing the likelihood of curative outcomes. Beyond worse patient outcomes, this also strains the healthcare system.   💷 The cost of A&E visits In 2024/25, the average cost for a 10-minute GP consultation was around £56. In contrast, an average A&E visit ranges from £137 to £445.   Given the huge number of people suffering from liver disease, by enabling better care to be delivered in the community, we have an opportunity to re-deploy millions on other initiatives.   As evidence grows linking late diagnosis of liver disease to emergency visits, it's clear that keeping people out of A&E should be a priority—not just for patient outcomes, but for healthcare efficiency.   🔗 For further reading: Multimorbidity and adverse outcomes in A&E: https://lnkd.in/esHWFxV6 Delayed diagnosis in cirrhosis and HCC patients: https://lnkd.in/eutveprF #LiverDisease #NHSEngland #PublicHealth